Mitra Debanjan, Paul Manish, Thatoi Hrudayanath, Mohapatra Pradeep K Das
Department of Microbiology, Raiganj University, Raiganj, West Bengal, India.
Department of Biotechnology, Maharaja Sriram Chandra Bhanja Deo University, Baripada, Odisha, India.
J Biomol Struct Dyn. 2022;40(20):10239-10249. doi: 10.1080/07391102.2021.1942210. Epub 2021 Jun 28.
In December 2019, COVID-19 epidemic was reported in Wuhan, China, and subsequently the infection has spread all over the world and became pandemic. The death toll associated with the pandemic is increasing day by day in a high rate. Herein, an effort has been made to identify the potentiality of commercially available drugs and also their probable derivatives for creation of better opportunity to make more powerful drugs against coronavirus. This study involves the interactions of dexamethasone and its derivatives against the multiple proteins of SARS-CoV-2 with the help of various computational methods. Descriptor parameters revealed their non-toxic effect in the human body. Ultimately docking studies and molecular dynamic simulation on those target protein by dexamethasone and its derivatives showed a high binding energy. Dexamethasone showed -9.8 kcal/mol and its derivative D5 showed -12.1 kcal/mol binding energy. Those scores indicate that dexamethasone has more therapeutic effect on SARS CoV-2 than other currently used drugs. Derivatives give the clue for the synthesis of a novel drug to remove SARS CoV-2. Until then, dexamethasone will be used as a potential inhibitor of SARS CoV-2.Communicated by Ramaswamy H. Sarma.
2019年12月,中国武汉报告了新冠疫情,随后感染蔓延至全球并成为大流行。与该大流行相关的死亡人数正以高速度逐日增加。在此,人们努力确定市售药物及其可能的衍生物的潜力,以便创造更好的机会来研发更有效的抗冠状病毒药物。本研究借助各种计算方法,研究了地塞米松及其衍生物与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)多种蛋白质的相互作用。描述符参数显示它们对人体无毒作用。最终,地塞米松及其衍生物对这些靶蛋白的对接研究和分子动力学模拟显示出高结合能。地塞米松的结合能为-9.8千卡/摩尔,其衍生物D5的结合能为-12.1千卡/摩尔。这些分数表明,地塞米松对SARS-CoV-2的治疗效果比其他目前使用的药物更好。衍生物为合成一种新型抗SARS-CoV-2药物提供了线索。在此之前,地塞米松将用作SARS-CoV-2的潜在抑制剂。由拉马斯瓦米·H·萨尔马传达。